Skip to main content

Peer Review reports

From: Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome

Original Submission
8 Jun 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
7 Jul 2021 Reviewed Reviewer Report
20 Sep 2021 Reviewed Reviewer Report
9 Oct 2021 Author responded Author comments - Xiao-Su Zhao
Resubmission - Version 4
9 Oct 2021 Submitted Manuscript version 4
22 Oct 2021 Reviewed Reviewer Report
6 Nov 2021 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
23 Nov 2021 Editorially accepted
3 Jan 2022 Article published 10.1186/s12885-021-09051-5

You can find further information about peer review here.

Back to article page